Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114566 · ClinicalTrials.gov registry record
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03114566: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03114566 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03114566 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.
Interventions
- OTHER Leukapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2021-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03114566
The ClinicalTrials.gov registry entry for NCT03114566 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leukapheresis is the first listed.
NCT03114566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03114566 about?
NCT03114566 is a clinical study titled "Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors". The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.
What is the current status of trial NCT03114566?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-04-05. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT03114566?
The interventions under investigation include: Leukapheresis (OTHER).
Who is sponsoring clinical trial NCT03114566?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.